CD27 and myeloid sarcoma: Specifically in lymphoid lineage, our findings reveal altered IC expression on CD20+CD27+, CD20-CD27+, CD20+CD27- B cells in MS patients compared to HCs, suggesting a disrupted immune environment that affects B cell activation.